Retrospective Study on the Incidence and Management of Anemia in Oncology

Completed

• Conditions: Anemia; Cancer

• Registration Number: NCT04779840
• Lead Sponsor: Weprom

Brief Summary

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).

Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.

Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-20
• Primary Completion: 2021-01-20
• Study Completion: 2021-01-20
• Status Verified: 2021-02
• Study First Submitted: 2021-02-26
• Study First Submitted QC: 2021-02-26
• Last Update Submitted: 2021-02-26
• Study First Posted: 2021-03-03
• Last Update Posted: 2021-03-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 349

Inclusion Criteria

• Age ≥ 18 years old,
• Follow-up for cancer justifying hospitalization,
• Presenting anemia defined by a hemoglobin level <11 g / dL,
• Patient not having objected to the collection of his data after oral and written information.

Exclusion Criteria

• patients with a hemoglobin level ≥ 11 g / dL,
• adult patients under guardianship, curatorship or deprived of liberty,
• pregnancy or breast-feeding in progress at the time of hospitalization.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of anemia	2 years	number of patient with anemia (\<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period

Secondary Outcome Measures

Name	Time	Method
Assessment of transfusion prescriptions	2 years	number of transfusions performed on the number of patients hospitalized over the period
Assessment of iron prescriptions	2 years	number of prescriptions of iron (oral and intravenous)
overall survival	2 years	Delay between the enrollment date and the date of patient's death
Assessment of erythropoiesis stimulating agents (EPO) prescriptions	2 years	number of prescriptions for erythropoiesis stimulating agents (EPO)
Time between last transfusion and date of death	2 years	Delay between the date of the last transfusion and the date of patient's death

Trial Locations

Locations (1)

Centre Jean Bernard - Clinique Victor Hugo; 🇫🇷 Le Mans, France